Kansas State University to Build Bulk Solids Innovation Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Kansas State University to Build Bulk Solids Innovation Center



Untitled Document

Kansas State University plans to build the Kansas State University Bulk Solids Innovation Center in Salina, Kansas, for companies that design and use systems for bulk solids. The center will be used to study and increase the understanding of bulk solids materials handling.

Primary partners in the projected $3.5-million, 13,000 ft2 facility are Kansas State University, the Salina Chamber of Commerce, the Salina Economic Development Corporation, and several private companies. The university will be the key tenant in the center with various offices and research suites for permanent and visiting researchers, companies, and other users. Two local companies, K-Tron and Vortex Valves, will be initial anchor tenants and will conduct both their own research as well as collaborative research with the university.

The building will include open and enclosed laboratory areas to allow for collaborative and proprietary research projects. The open area will also allow for the more exploratory/open-access research conducted by university investigators and students. The center will incorporate Kansas State faculty from the technology, engineering, and agriculture programs. It will focus on the process industries of plastics, foods and chemicals and will complement the College of Agriculture's Bulk Solids and Particle Technology Lab and program housed on the university's Manhattan, Kansas campus. The project will use public and private sector resources, including a $1-million-plus grant through the Economic Development Assistance Programs of the US Department of Commerce's Economic Development Administration.

Source: K-Tron

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here